Keith Grimwood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8700848/publications.pdf

Version: 2024-02-01

293 papers

12,867 citations

58 h-index 95 g-index

299 all docs 299 docs citations

times ranked

299

10501 citing authors

#	Article	IF	CITATIONS
1	Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, e35-e43.	0.3	8
2	The Initial Timing and Burden of Viral Gastrointestinal Infections in Australian Infants. Journal of Pediatric Gastroenterology and Nutrition, 2022, 74, .	0.9	3
3	Respiratory virus detection during the COVIDâ€19 pandemic in Queensland, Australia. Australian and New Zealand Journal of Public Health, 2022, 46, 10-15.	0.8	28
4	Association of childhood tracheomalacia with bronchiectasis: a case–control study. Archives of Disease in Childhood, 2022, 107, 565-569.	1.0	8
5	Ciprofloxacin-associated Peripheral Neuropathy in a Child: A Case Report and Review of the Literature. Pediatric Infectious Disease Journal, 2022, 41, 121-122.	1.1	2
6	<i>Streptococcus anginosus</i> group infections in hospitalised children and young people. Journal of Paediatrics and Child Health, 2022, 58, 809-814.	0.4	4
7	Potentially Pathogenic Organisms in Stools and Their Association With Acute Diarrheal Illness in Children Aged & Diarrheal	0.6	4
8	Association between vaccination status, symptom identification and healthcare use: Implications for test negative design observational studies. Vaccine, 2022, 40, 1918-1923.	1.7	0
9	Factors in childhood associated with lung function decline to adolescence in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 977-983.	0.3	4
10	Characterization of the Phase-Variable Autotransporter Lav Reveals a Role in Host Cell Adherence and Biofilm Formation in Nontypeable Haemophilus influenzae. Infection and Immunity, 2022, 90, e0056521.	1.0	2
11	Extended Versus Standard Antibiotic Course Duration in Children <5 Years of Age Hospitalized With Community-acquired Pneumonia in High-risk Settings: Four-week Outcomes of a Multicenter, Double-blind, Parallel, Superiority Randomized Controlled Trial. Pediatric Infectious Disease Journal, 2022, 41, 549-555.	1.1	10
12	Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2×2 partial factorial, randomised controlled trial. BMJ Open Respiratory Research, 2022, 9, e001236.	1.2	0
13	International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net. European Respiratory Journal, 2022, 59, 2200264.	3.1	8
14	Histo-blood group antigens and rotavirus vaccine virus shedding in Australian infants. Pathology, 2022, 54, 928-934.	0.3	3
15	Communityâ€level burden of acute diarrhoeal illness in the first 2 years of life in Brisbane, Australia: A birth cohort study. Journal of Paediatrics and Child Health, 2021, 57, 140-146.	0.4	2
16	Epidemiology of respiratory syncytial virus in a community birth cohort of infants in the first 2 years of life. European Journal of Pediatrics, 2021, 180, 2125-2135.	1.3	12
17	European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. European Respiratory Journal, 2021, 58, 2002990.	3.1	95
18	Medication and healthcare use, parent knowledge and cough in children: A cohort study. Pediatric Pulmonology, 2021, 56, 2345-2354.	1.0	3

#	Article	IF	Citations
19	Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa. Drugs in R and D, 2021, 21, 203-215.	1.1	2
20	Clinical and research priorities for children and young people with bronchiectasis: an international roadmap. ERJ Open Research, 2021, 7, 00122-2021.	1.1	28
21	Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115329.	0.8	2
22	Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use. Clinical Microbiology Reviews, 2021, 34, e0002821.	5.7	19
23	Cordâ€blood respiratory syncytial virus antibodies and respiratory health in first 5 years of life. Pediatric Pulmonology, 2021, 56, 3942-3951.	1.0	4
24	The role of mobile phones as a possible pathway for pathogen movement, a cross-sectional microbial analysis. Travel Medicine and Infectious Disease, 2021, 43, 102095.	1.5	9
25	Management of children and adolescents with bronchiectasis: summary of the ERS clinical practice guideline. Breathe, 2021, 17, 210105.	0.6	8
26	Children's Bronchiectasis Education Advocacy and Research Network (Child-BEAR-Net): an ERS Clinical Research Collaboration on improving outcomes of children and adolescents with bronchiectasis. European Respiratory Journal, 2021, 58, 2101657.	3.1	9
27	Is there an association between tracheomalacia and bronchiectasis in children?., 2021,,.		1
28	Predictors of the Development of Protracted Bacterial Bronchitis following Presentation to Healthcare for an Acute Respiratory Illness with Cough: Analysis of Three Cohort Studies. Journal of Clinical Medicine, 2021, 10, 5735.	1.0	5
29	Study Protocol for Preventing Early-Onset Pneumonia in Young Children Through Maternal Immunisation: A Multi-Centre Randomised Controlled Trial (PneuMatters). Frontiers in Pediatrics, 2021, 9, 781168.	0.9	2
30	Parechovirus A Infections in Healthy Australian Children During the First 2 Years of Life: A Community-based Longitudinal Birth Cohort Study. Clinical Infectious Diseases, 2020, 71, 116-127.	2.9	9
31	\hat{l}^2 -lactam antibiotic versus combined \hat{l}^2 -lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis. International Journal of Antimicrobial Agents, 2020, 55, 105839.	1.1	21
32	The Respiratory Specimen Collection Trial (ReSpeCT): A Randomized Controlled Trial to Compare Quality and Timeliness of Respiratory Sample Collection in the Home by Parents and Healthcare Workers From Children Aged & Dit; 2 Years. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 134-141.	0.6	21
33	Over-diagnosis of Rotavirus Infection in Infants Due to Detection of Vaccine Virus. Clinical Infectious Diseases, 2020, 71, 1324-1326.	2.9	5
34	Effect of Definitions of Acute Gastroenteritis Episodes Using Symptom Diaries in Paediatric Cohorts. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, e54-e58.	0.9	4
35	Endemic Non–SARS-CoV-2 Human Coronaviruses in a Community-Based Australian Birth Cohort. Pediatrics, 2020, 146, .	1.0	12
36	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	7

#	Article	IF	CITATIONS
37	Risk Factors for Chronic Cough in Young Children: A Cohort Study. Frontiers in Pediatrics, 2020, 8, 444.	0.9	3
38	Azithromycin Prescribing by Respiratory Pediatricians in Australia and New Zealand for Chronic Wet Cough: A Questionnaire-Based Survey. Frontiers in Pediatrics, 2020, 8, 519.	0.9	7
39	Parainfluenza Virus Infection in an Australian Community-based Birth Cohort. Pediatric Infectious Disease Journal, 2020, 39, e284-e287.	1.1	5
40	Cost of hospitalization for bronchiectasis exacerbation in children. Respirology, 2020, 25, 1250-1256.	1.3	31
41	Bacterial colonization dynamics associated with respiratory syncytial virus during early childhood. Pediatric Pulmonology, 2020, 55, 1237-1245.	1.0	13
42	Total bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 923-930.	0.3	15
43	Antibiotics for Childhood Pneumonia — Do We Really Know How Long to Treat?. New England Journal of Medicine, 2020, 383, 77-79.	13.9	36
44	A decade on: Followâ€up findings of indigenous children with bronchiectasis. Pediatric Pulmonology, 2020, 55, 975-985.	1.0	15
45	Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort. European Respiratory Journal, 2020, 55, 1901694.	3.1	14
46	Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study. BMC Health Services Research, 2019, 19, 561.	0.9	23
47	Environmentally Persistent Free Radicals: Linking Air Pollution and Poor Respiratory Health?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1062-1063.	2.5	25
48	Effectiveness of a chronic cough management algorithm at the transitional stage from acute to chronic cough in children: a multicenter, nested, single-blind, randomised controlled trial. The Lancet Child and Adolescent Health, 2019, 3, 889-898.	2.7	19
49	Efficacy of oral amoxicillin–clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 791-801.	5.2	37
50	Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. The Lancet Global Health, 2019, 7, e861-e871.	2.9	213
51	Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis. Thorax, 2019, 74, 740-748.	2.7	15
52	Do combined upper airway cultures identify lower airway infections in children with chronic cough?. Pediatric Pulmonology, 2019, 54, 907-913.	1.0	12
53	HOspitalised Pneumonia Extended (HOPE) Study to reduce the long-term effects of childhood pneumonia: protocol for a multicentre, double-blind, parallel, superiority randomised controlled trial. BMJ Open, 2019, 9, e026411.	0.8	2
54	Analysis of Invasive Nontypeable <i>Haemophilus influenzae</i> Isolates Reveals Selection for the Expression State of Particular Phase-Variable Lipooligosaccharide Biosynthetic Genes. Infection and Immunity, 2019, 87, .	1.0	20

#	Article	IF	Citations
55	Detection of Epidemic Scarlet Fever Group A Streptococcus in Australia. Clinical Infectious Diseases, 2019, 69, 1232-1234.	2.9	19
56	Abolition of Pseudomonas aeruginosa AUSTâ€01 from an Australian CF center: Do other strains remain?. Pediatric Pulmonology, 2019, 54, 515-516.	1.0	0
57	Contemporary Concise Review 2018: Bronchiectasis. Respirology, 2019, 24, 382-389.	1.3	0
58	Earlyâ€onset group B streptococcal disease in a risk factorâ€based prevention setting: A 15â€year populationâ€based study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 422-429.	0.4	8
59	Differences in the lower airway microbiota of infants with and without cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 646-652.	0.3	16
60	Paediatric and adult bronchiectasis: Vaccination in prevention and management. Respirology, 2019, 24, 107-114.	1.3	6
61	Multiâ€eentre ethics and research governance review can impede nonâ€interventional clinical research. Internal Medicine Journal, 2019, 49, 722-728.	0.5	11
62	Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review. International Journal of Antimicrobial Agents, 2019, 53, 234-245.	1.1	45
63	A new dawn: inhaled antibiotics for patients with bronchiectasis. Lancet Respiratory Medicine, the, 2019, 7, 188-189.	5.2	5
64	Nasal swab bacteriology by PCR during the first 24â€months of life: A prospective birth cohort study. Pediatric Pulmonology, 2019, 54, 289-296.	1.0	17
65	Aspergillus and progression of lung disease in children with cystic fibrosis. Thorax, 2019, 74, 125-131.	2.7	32
66	Probiotics for preventing acute otitis media in children. The Cochrane Library, 2019, 6, CD012941.	1.5	13
67	Global Review of the Age Distribution of Rotavirus Disease in Children Aged <5 Years Before the Introduction of Rotavirus Vaccination. Clinical Infectious Diseases, 2019, 69, 1071-1078.	2.9	38
68	The point prevalence of respiratory syncytial virus in hospital and community-based studies in children from Northern Australia: studies in a $\hat{a} \in \mathbb{N}$ population., 2019,,.		0
69	Oral antibiotics vs placebo for exacerbations of paediatric bronchiectasis., 2019,,.		0
70	The point prevalence of respiratory syncytial virus in hospital and community-based studies in children from Northern Australia: studies in a †high-risk†population. Rural and Remote Health, 2019, 19, 5267.	0.4	0
71	Timing of First Respiratory Virus Detections in Infants: A Community-Based Birth Cohort Study. Journal of Infectious Diseases, 2018, 217, 418-427.	1.9	28
72	Multivalent Rotavirus Vaccine and Wild-type Rotavirus Strain Shedding in Australian Infants: A Birth Cohort Study. Clinical Infectious Diseases, 2018, 66, 1411-1418.	2.9	18

#	Article	lF	CITATIONS
73	Defining lower airway bacterial infection in children with chronic endobronchial disorders. Pediatric Pulmonology, 2018, 53, 224-232.	1.0	26
74	Defining chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 292-293.	0.3	5
75	Meteorological factors and respiratory syncytial virus seasonality in subtropical Australia. Epidemiology and Infection, 2018, 146, 757-762.	1.0	20
76	Defining †healthy' in preschoolâ€aged children for forced oscillation technique reference equations. Respirology, 2018, 23, 406-413.	1.3	11
77	Viruses causing lower respiratory symptoms in young children: findings from the ORChID birth cohort. Thorax, 2018, 73, 969-979.	2.7	45
78	The NICE-GUT trial protocol: a randomised, placebo controlled trial of oral nitazoxanide for the empiric treatment of acute gastroenteritis among Australian Aboriginal children. BMJ Open, 2018, 8, e019632.	0.8	10
79	Clinical course of chronic suppurative lung disease and bronchiectasis in Alaska Native children. Pediatric Pulmonology, 2018, 53, 1662-1669.	1.0	12
80	Bronchiectasis in children: diagnosis and treatment. Lancet, The, 2018, 392, 866-879.	6.3	182
81	Amoxicillin–clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet, The, 2018, 392, 1197-1206.	6.3	51
82	Response to "Bacteria from bronchoalveolar lavage fluid from children with suspected chronic lower respiratory tract infection: results from a multi-center, cross-sectional study in Spain―Eur J Pediatr (2018) 177:181–192. European Journal of Pediatrics, 2018, 177, 1409-1410.	1.3	0
83	Bacteria and viruses in the nasopharynx immediately prior to onset of acute lower respiratory infections in Indigenous Australian children. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1785-1794.	1.3	9
84	The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial. Human Vaccines and Immunotherapeutics, 2018, 14, 1-12.	1.4	11
85	Effectiveness of a cough management algorithm at the transitional phase from acute to chronic cough in Australian children aged <15â€years: protocol for a randomised controlled trial. BMJ Open, 2017, 7, e013796.	0.8	10
86	Impact and effectiveness of childhood varicella vaccine program in Queensland, Australia. Vaccine, 2017, 35, 3490-3497.	1.7	13
87	The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. Thorax, 2017, 72, 1104-1112.	2.7	90
88	Detection of viruses in weekly stool specimens collected during the first 2 years of life: A pilot study of five healthy Australian infants in the rotavirus vaccine era. Journal of Medical Virology, 2017, 89, 917-921.	2.5	19
89	ERS statement on protracted bacterial bronchitis in children. European Respiratory Journal, 2017, 50, 1602139.	3.1	137
90	<i>Streptococcus pneumoniae</i> and chronic endobronchial infections in childhood. Pediatric Pulmonology, 2017, 52, 1532-1545.	1.0	7

#	Article	IF	CITATIONS
91	The airway microbiota in early cystic fibrosis lung disease. Pediatric Pulmonology, 2017, 52, 1384-1404.	1.0	37
92	Upper airway viruses and bacteria and clinical outcomes in children with cough. Pediatric Pulmonology, 2017, 52, 373-381.	1.0	18
93	The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis. Frontiers in Pediatrics, 2017, 5, 58.	0.9	5
94	Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis. BMC Pulmonary Medicine, 2017, 17, 138.	0.8	11
95	Necrotizing pneumonia: an emerging problem in children?. Pneumonia (Nathan Qld), 2017, 9, 11.	2.5	80
96	Saksenaeae Subcutaneous Abscess in an Immunocompetent Child. Pediatric Infectious Disease Journal, 2016, 35, 120.	1.1	1
97	Pediatric bronchiectasis: No longer an orphan disease. Pediatric Pulmonology, 2016, 51, 450-469.	1.0	125
98	Respiratory Viruses in Neonates. Pediatric Infectious Disease Journal, 2016, 35, 1355-1357.	1.1	8
99	<pre><scp><i>P</i>/i></scp><i>seudomonas aeruginosa</i> antibiotic resistance in <scp>A</scp>ustralian cystic fibrosis centres. Respirology, 2016, 21, 329-337.</pre>	1.3	43
100	Antibiotics in childhood pneumonia: how long is long enough?. Pneumonia (Nathan Qld), 2016, 8, 6.	2.5	14
101	74 Emergence of a shared Pseudomonas aeruginosa strain within an adult cystic fibrosis centre. Journal of Cystic Fibrosis, 2016, 15, S70.	0.3	2
102	Paediatric chronic suppurative lung disease: clinical characteristics and outcomes. European Journal of Pediatrics, 2016, 175, 1077-1084.	1.3	29
103	Protracted bacterial bronchitis: The last decade and the road ahead. Pediatric Pulmonology, 2016, 51, 225-242.	1.0	126
104	The burden of community-managed acute respiratory infections in the first 2-years of life. Pediatric Pulmonology, 2016, 51, 1336-1346.	1.0	62
105	Febrile Seizures in the Era of Rotavirus Vaccine: Table 1 Journal of the Pediatric Infectious Diseases Society, 2016, 5, 206-209.	0.6	23
106	Earlyâ€onset neonatal group B streptococcus sepsis following national riskâ€based prevention guidelines. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 69-74.	0.4	32
107	Prevalence, codetection and seasonal distribution of upper airway viruses and bacteria in children with acute respiratory illnesses with cough as a symptom. Clinical Microbiology and Infection, 2016, 22, 527-534.	2.8	15
108	Long-term effects of pneumonia in young children. Pneumonia (Nathan Qld), 2015, 6, 101-114.	2.5	25

#	Article	IF	CITATIONS
109	Childhood Pneumonia Screener: a concept. Pneumonia (Nathan Qld), 2015, 6, i-ii.	2.5	1
110	Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Medical Journal of Australia, 2015, 202, 21-23.	0.8	133
111	Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium. Frontiers in Microbiology, 2015, 6, 1036.	1.5	144
112	Toward Making Inroads in Reducing the Disparity of Lung Health in Australian Indigenous and New Zealand MÃ,,Âori Children. Frontiers in Pediatrics, 2015, 3, 9.	0.9	33
113	Three-Weekly Doses of Azithromycin for Indigenous Infants Hospitalized with Bronchiolitis: A Multicentre, Randomized, Placebo-Controlled Trial. Frontiers in Pediatrics, 2015, 3, 32.	0.9	28
114	Long-term effects of pneumonia in young children. Pneumonia (Nathan Qld), 2015, 6, 101.	2.5	22
115	Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis. PLoS ONE, 2015, 10, e0144022.	1.1	17
116	Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. Journal of Cystic Fibrosis, 2015, 14, 361-369.	0.3	61
117	Vaccination against respiratory (i) Pseudomonas aeruginosa (i) infection. Human Vaccines and Immunotherapeutics, 2015, 11, 14-20.	1.4	62
118	Further clinical trials on macrolides for bronchiolitis in infants are unnecessary. Journal of Allergy and Clinical Immunology, 2015, 136, 1134-1135.	1.5	1
119	Acquisition of Human Polyomaviruses in the First 18 Months of Life. Emerging Infectious Diseases, 2015, 21, 365-367.	2.0	23
120	Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2275-2285.	1.3	50
121	PBB: definition, mechanisms, and treatment. Lancet Respiratory Medicine, the, 2015, 3, 743-744.	5.2	13
122	Reduced risk of pertussis in whole-cell compared to acellular vaccine recipients is not confounded by age or receipt of booster-doses. Vaccine, 2015, 33, 5027-5030.	1.7	14
123	Comparison of Test Specificities of Commercial Antigen-Based Assays and In-House PCR Methods for Detection of Rotavirus in Stool Specimens. Journal of Clinical Microbiology, 2015, 53, 295-297.	1.8	24
124	Acellular pertussis vaccine effectiveness for children during the 2009–2010Âpertussis epidemic in Queensland. Medical Journal of Australia, 2014, 200, 334-338.	0.8	25
125	Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations. Expert Review of Respiratory Medicine, 2014, 8, 43-55.	1.0	10
126	Mutual Exclusivity of Hyaluronan and Hyaluronidase in Invasive Group A Streptococcus. Journal of Biological Chemistry, 2014, 289, 32303-32315.	1.6	30

#	Article	IF	CITATIONS
127	Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Review of Vaccines, 2014, 13, 1081-1106.	2.0	96
128	Viability of <i>Pseudomonas aeruginosa </i> in cough aerosols generated by persons with cystic fibrosis. Thorax, 2014, 69, 740-745.	2.7	79
129	Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatric Pulmonology, 2014, 49, 189-200.	1.0	85
130	A retrospective performance evaluation of an adenovirus realâ€time PCR assay. Journal of Medical Virology, 2014, 86, 795-801.	2.5	11
131	Absence of an Important Vaccine and Diagnostic Target in Carriage- and Disease-Related Nontypeable Haemophilus influenzae. Vaccine Journal, 2014, 21, 250-252.	3.2	33
132	Bronchiectasis: the arrival of better evidence. Lancet Respiratory Medicine, the, 2014, 2, 12-13.	5.2	8
133	Nasal swab samples and real-time polymerase chain reaction assays in community-based, longitudinal studies of respiratory viruses: the importance of sample integrity and quality control. BMC Infectious Diseases, 2014, 14, 15.	1.3	41
134	Costs of Bronchoalveolar Lavage-Directed Therapy in the First 5ÂYears of Life for Children with Cystic Fibrosis. Journal of Pediatrics, 2014, 165, 564-569.e5.	0.9	16
135	Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Review of Anti-Infective Therapy, 2014, 12, 1277-1296.	2.0	27
136	Does failed chronic wet cough response to antibiotics predict bronchiectasis?. Archives of Disease in Childhood, 2014, 99, 522-525.	1.0	49
137	A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis. BMC Infectious Diseases, 2014, 14, 307.	1.3	20
138	Respiratory Exacerbations in Indigenous Children From Two Countries With Non-Cystic Fibrosis Chronic Suppurative Lung Disease/Bronchiectasis. Chest, 2014, 146, 762-774.	0.4	39
139	Bronchoscopy contributes to the clinical management of indigenous children newly diagnosed with bronchiectasis. Pediatric Pulmonology, 2013, 48, 67-73.	1.0	43
140	Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial. Trials, 2013, 14, 53.	0.7	16
141	Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial. Trials, 2013, 14. 282.	0.7	17
142	Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respiratory Medicine, the, 2013, 1, 610-620.	5.2	157
143	Quantitative PCR confirms culture as the gold standard for detection of lower airway infection by nontypeable Haemophilus influenzae in Australian Indigenous children with bronchiectasis. Journal of Microbiological Methods, 2013, 92, 270-272.	0.7	11
144	High-throughput single-nucleotide polymorphism-based typing of shared Pseudomonas aeruginosa strains in cystic fibrosis patients using the Sequenom iPLEX platform. Journal of Medical Microbiology, 2013, 62, 734-740.	0.7	9

#	Article	lF	Citations
145	Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1583-1592.	1.3	23
146	Mucosal and systemic antibody responses to potentialPseudomonas aeruginosavaccine protein antigens in young children with cystic fibrosis following colonization and infection. Human Vaccines and Immunotherapeutics, 2013, 9, 506-514.	1.4	24
147	Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening. Clinical Microbiology and Infection, 2013, 19, 266-272.	2.8	19
148	Shared < i > Pseudomonas aeruginosa < l i > genotypes are common in Australian cystic fibrosis centres. European Respiratory Journal, 2013, 41, 1091-1100.	3.1	59
149	<i>Nocardia brasiliensis</i> Infection Mimicking Juvenile Idiopathic Arthritis in a 4-Year-Old Girl. Pediatrics, 2013, 132, e1424-e1427.	1.0	8
150	Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5â€years of age. Thorax, 2013, 68, 643-651.	2.7	83
151	The Burden of Childhood Pneumonia in the Developed World. Pediatric Infectious Disease Journal, 2013, 32, e119-e127.	1.1	64
152	Longitudinal Nasopharyngeal Carriage and Antibiotic Resistance of Respiratory Bacteria in Indigenous Australian and Alaska Native Children with Bronchiectasis. PLoS ONE, 2013, 8, e70478.	1.1	32
153	Improving the Diagnosis, Management, and Outcomes of Children with Pneumonia: Where are the Gaps?. Frontiers in Pediatrics, $2013, 1, 29$.	0.9	28
154	Evidence of false-positive results in a commercially available rotavirus assay in the vaccine era, Australia, 2011 to 2012 . Eurosurveillance, 2013 , 18 , .	3.9	13
155	Evidence of false-positive results in a commercially available rotavirus assay in the vaccine era, Australia, 2011 to 2012. Eurosurveillance, 2013, 18, .	3.9	8
156	Active surveillance of serious adverse drug reactions in New Zealand children: Table 1. Archives of Disease in Childhood, 2012, 97, 761-762.	1.0	2
157	Unexpectedly Limited Durability of Immunity Following Acellular Pertussis Vaccination in Preadolescents in a North American Outbreak. Clinical Infectious Diseases, 2012, 55, 1434-1435.	2.9	12
158	Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease Protection. JAMA - Journal of the American Medical Association, 2012, 308, 454.	3.8	220
159	Culture and PCR Detection of Haemophilus influenzae and Haemophilus haemolyticus in Australian Indigenous Children with Bronchiectasis. Journal of Clinical Microbiology, 2012, 50, 2444-2445.	1.8	31
160	Observational Research in Childhood Infectious Diseases (ORChID): a dynamic birth cohort study: TableÂ1. BMJ Open, 2012, 2, e002134.	0.8	63
161	Prevention of neonatal group B streptococcus disease in the 21st century. Journal of Paediatrics and Child Health, 2012, 48, 808-815.	0.4	24
162	Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial. Trials, 2012, 13, 156.	0.7	14

#	Article	IF	Citations
163	Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in Indigenous Australian children with non-cystic fibrosis bronchiectasis. International Journal of Antimicrobial Agents, 2012, 40, 365-369.	1.1	27
164	Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial. BMC Pediatrics, 2012, 12, 122.	0.7	22
165	Comparison of DNA Extraction Methods for Microbial Community Profiling with an Application to Pediatric Bronchoalveolar Lavage Samples. PLoS ONE, 2012, 7, e34605.	1.1	126
166	Pseudomonas aeruginosa Exhibits Frequent Recombination, but Only a Limited Association between Genotype and Ecological Setting. PLoS ONE, 2012, 7, e44199.	1.1	114
167	Lower airway microbiology and cellularity in children with newly diagnosed non F bronchiectasis. Pediatric Pulmonology, 2012, 47, 300-307.	1.0	95
168	Flexible bronchoscopy in managing a child with pulmonary hydatid disease. Pediatric Pulmonology, 2012, 47, 1140-1142.	1.0	4
169	Increases in Australian cutaneous abscess hospitalisations: 1999–2008. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 93-96.	1.3	18
170	Canadian rotavirus vaccine effectiveness data. Canadian Family Physician, 2012, 58, 1081.	0.1	0
171	Effect of Bronchoalveolar Lavage–Directed Therapy on Pseudomonas aeruginosa Infection and Structural Lung Injury in Children With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2011, 306, 163-71.	3.8	170
172	Community-associated Methicillin-resistant Staphylococcus aureus Causing Orbital Cellulitis in Australian Children. Pediatric Infectious Disease Journal, 2011, 30, 1003-1006.	1.1	26
173	Reduction in Rotavirus-associated Acute Gastroenteritis Following Introduction of Rotavirus Vaccine Into Australia's National Childhood Vaccine Schedule. Pediatric Infectious Disease Journal, 2011, 30, S25-S29.	1.1	192
174	Variation in erythromycin and clindamycin resistance patterns between New Zealand and Australian group B streptococcus isolates. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2011, 51, 328-332.	0.4	7
175	Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time PCR and high-resolution melting curve analysis. Clinical Microbiology and Infection, 2011, 17, 1403-1408.	2.8	12
176	Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatric Respiratory Reviews, 2011, 12, 111-118.	1.2	41
177	Clonal complex Pseudomonas aeruginosa in horses. Veterinary Microbiology, 2011, 149, 508-512.	0.8	25
178	Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol. Trials, 2011, 12, 94.	0.7	16
179	Comparison of Three Molecular Techniques for Typing <i>Pseudomonas aeruginosa</i> Isolates in Sputum Samples from Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 263-268.	1.8	78
180	Respiratory Bacterial Pathogens in the Nasopharynx and Lower Airways of Australian Indigenous Children with Bronchiectasis. Journal of Pediatrics, 2010, 157, 1001-1005.	0.9	103

#	Article	IF	Citations
181	Geographical differences in the proportion of human group A rotavirus strains within New Zealand during one epidemic season. Journal of Medical Virology, 2010, 82, 897-902.	2.5	7
182	Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation. Medical Journal of Australia, 2010, 193, 356-365.	0.8	120
183	Pentavalent Rotavirus Vaccine and Prevention of Gastroenteritis Hospitalizations in Australia. Pediatrics, 2010, 126, e506-e512.	1.0	109
184	Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax, 2010, 65, 985-990.	2.7	34
185	Rotavirus Infections and Vaccines. Paediatric Drugs, 2010, 12, 235-256.	1.3	58
186	A cross-sectional survey of influenza A infection, and management practices in small rural backyard poultry flocks in two regions of New Zealand. New Zealand Veterinary Journal, 2010, 58, 74-80.	0.4	23
187	Multilocus sequence typing (MLST) of Pseudomonas aeruginosa collected from different ecological niches. Journal of Cystic Fibrosis, 2010, 9, S30.	0.3	1
188	Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Medical Journal of Australia, 2009, 191, 157-160.	0.8	110
189	Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2009, 47, 1503-1509.	1.8	52
190	Rotavirus vaccines: Opportunities and challenges. Hum Vaccin, 2009, 5, 57-69.	2.4	52
191	Budget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedule. Value in Health, 2009, 12, 888-898.	0.1	37
192	Successful treatment of cepacia syndrome. Journal of Cystic Fibrosis, 2009, 8, 291-293.	0.3	24
193	Acute and Persistent Diarrhea. Pediatric Clinics of North America, 2009, 56, 1343-1361.	0.9	37
194	Should rotavirus vaccines be included in the national immunization program of a small developed country?. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 401-404.	0.7	3
195	Safety of bronchoalveolar lavage in young children with cystic fibrosis. Pediatric Pulmonology, 2008, 43, 965-972.	1.0	48
196	Human rotavirus vaccines: too early for the strain to tell. Lancet, The, 2008, 371, 1144-1145.	6.3	44
197	Pseudomonas aeruginosa transmission is infrequent in New Zealand cystic fibrosis clinics. European Respiratory Journal, 2008, 32, 1583-1590.	3.1	12
198	Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand. Epidemiology and Infection, 2008, 136, 1333-1341.	1.0	47

#	Article	IF	CITATIONS
199	Management of bronchiectasis and chronic suppurative lung disease in Indigenous children and adults from rural and remote Australian communities. Medical Journal of Australia, 2008, 189, 386-393.	0.8	68
200	Novel Neutrophil-Derived Proteins in Bronchoalveolar Lavage Fluid Indicate an Exaggerated Inflammatory Response in Pediatric Cystic Fibrosis Patients. Clinical Chemistry, 2007, 53, 1782-1791.	1.5	45
201	Clinical update: rotavirus gastroenteritis and its prevention. Lancet, The, 2007, 370, 302-304.	6.3	54
202	Rotavirus vaccines must perform in low-income countries too. Lancet, The, 2007, 370, 1739-1740.	6.3	20
203	PGI4 INCLUSION OF A PENTAVALENT ROTAVIRUS VACCINE IN THE NEW ZEALAND CHILDHOOD IMMUNISATION SCHEDULE. Value in Health, 2007, 10, A148.	0.1	O
204	Human Bocavirus in Infants, New Zealand. Emerging Infectious Diseases, 2007, 13, 1797-1799.	2.0	16
205	Mycoplasma pneumoniae infection complicated by pneumomediastinum and severe mucositis. Journal of Paediatrics and Child Health, 2007, 43, 403-405.	0.4	16
206	Infants hospitalised with pertussis: Estimating the true disease burden. Journal of Paediatrics and Child Health, 2007, 43, 617-622.	0.4	29
207	Rotavirus hospitalisation in New Zealand children under 3 years of age. Journal of Paediatrics and Child Health, 2006, 42, 196-203.	0.4	21
208	Distinct patterns of evolution between respiratory syncytial virus subgroups A and B From New Zealand isolates collected over thirty-seven years. Journal of Medical Virology, 2006, 78, 1354-1364.	2.5	37
209	Unraveling rotaviruses, oral vaccines and intussusception. Journal of Paediatrics and Child Health, 2005, 41, 471-472.	0.4	1
210	Another vaccine, another step forward?. Journal of Paediatrics and Child Health, 2005, 41, 541-542.	0.4	0
211	Vitamin A and E deficiency and lung disease in infants with cystic fibrosis Journal of Paediatrics and Child Health, 2005, 41, 663-668.	0.4	23
212	Lower Airway Inflammation in Infants with Cystic Fibrosis Detected by Newborn Screening. Pediatric Pulmonology, 2005, 40, 500-510.	1.0	205
213	Intussusception and rotavirus associated hospitalisation in New Zealand. Archives of Disease in Childhood, 2005, 90, 1077-1081.	1.0	50
214	Effects of Segregation on an EpidemicPseudomonas aeruginosaStrain in a Cystic Fibrosis Clinic. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1020-1025.	2.5	77
215	Tuberculosis in New Zealand, 1992-2001: a resurgence. Archives of Disease in Childhood, 2005, 90, 1157-1161.	1.0	25
216	Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet, The, 2005, 366, 394-396.	6.3	70

#	Article	IF	CITATIONS
217	Emergence of Echovirus Type 13 as a Prominent Enterovirus. Clinical Infectious Diseases, 2004, 38, 70-77.	2.9	52
218	Cognitive and Executive Function 12 Years after Childhood Bacterial Meningitis: Effect of Acute Neurologic Complications and Age of Onset. Journal of Pediatric Psychology, 2004, 29, 67-81.	1.1	82
219	Macro-AST: A benign cause of persistently elevated aspartate aminotransferase. Journal of Paediatrics and Child Health, 2004, 40, 642-643.	0.4	11
220	Persistent renal cortical scintigram defects in children 2Âyears after urinary tract infection. Pediatric Radiology, 2004, 34, 465-471.	1.1	37
221	The prevention of early-onset neonatal group B streptococcus infection: technical report from the New Zealand GBS Consensus Working Party. New Zealand Medical Journal, 2004, 117, U1023.	0.5	12
222	Variations in bronchiolitis management between five New Zealand hospitals: Can we do better?. Journal of Paediatrics and Child Health, 2003, 39, 40-45.	0.4	52
223	Acute Flaccid Paralysis from Echovirus Type 33 Infection. Journal of Clinical Microbiology, 2003, 41, 2230-2232.	1.8	26
224	An Echovirus Type 33 Winter Outbreak in New Zealand. Clinical Infectious Diseases, 2003, 37, 650-657.	2.9	28
225	QUALITY OF DRINKING-WATER AND ITS RELATION TO GASTROINTESTINAL DISEASE IN CHILDREN Epidemiology, 2003, 14, S70-S371.	1.2	0
226	Classical Kawasaki disease in a neonate. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2002, 86, 135F-136.	1.4	37
227	Detection of a Widespread Clone ofPseudomonas aeruginosain a Pediatric Cystic Fibrosis Clinic. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 983-987.	2.5	176
228	Early airway infection, inflammation, and lung function in cystic fibrosis. Archives of Disease in Childhood, 2002, 87, 306-311.	1.0	108
229	Energy metabolism in infants with cystic fibrosis. Journal of Pediatrics, 2002, 140, 527-533.	0.9	32
230	Bronchiectasis in Indigenous children in remote Australian communities. Medical Journal of Australia, 2002, 177, 200-204.	0.8	193
231	Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. Journal of Paediatrics and Child Health, 2002, 38, 550-554.	0.4	27
232	Early-onset neonatal group B streptococcal infections in New Zealand 1998â^1999. Journal of Paediatrics and Child Health, 2002, 38, 272-277.	0.4	28
233	Cost-effectiveness of palivizumab in New Zealand. Journal of Paediatrics and Child Health, 2002, 38, 352-357.	0.4	41
234	Late antenatal carriage of group B Streptococcus by New Zealand women. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2002, 42, 182-186.	0.4	29

#	Article	IF	CITATIONS
235	Early-onset group B Streptococcus prevention protocols in New Zealand public hospitals. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2002, 42, 363-365.	0.4	2
236	Time course of transient cortical scintigraphic defects associated with acute pyelonephritis. Pediatric Radiology, 2002, 32, 849-852.	1.1	31
237	Awareness, knowledge and attitudes of lead maternity carers towards early-onset neonatal group B streptococcal disease. New Zealand Medical Journal, 2002, 115, 106-8.	0.5	2
238	Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Pediatrics, 2001, 138, 699-704.	0.9	390
239	Legacy of bacterial meningitis in infancy. BMJ: British Medical Journal, 2001, 323, 523-524.	2.4	10
240	Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal, 2001, 20, 240-246.	1.1	61
241	Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. European Respiratory Journal, 2001, 17, 281-286.	3.1	110
242	Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. Archives of Disease in Childhood, 2000, 83, 111-116.	1.0	228
243	Bacteraemia in febrile children presenting to a paediatric emergency department. Medical Journal of Australia, 1999, 170, 475-478.	0.8	48
244	Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis., 1999, 28, 321-328.		306
245	Severe viral respiratory infections in infants with cystic fibrosis., 1998, 26, 371-379.		169
246	Renal tuberculosis in an Australianâ€born child. Journal of Paediatrics and Child Health, 1998, 34, 293-295.	0.4	3
247	Extended excretion of rotavirus after severe diarrhoea in young children. Lancet, The, 1998, 351, 1844-1848.	6.3	141
248	Central nervous system tuberculosis after resolution of miliary tuberculosis. Pediatric Infectious Disease Journal, 1998, 17, 519-523.	1.1	18
249	Surfactant Composition in Infants and Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 161-165.	2.5	73
250	Lower Airway Inflammation in Infants and Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1197-1204.	2.5	449
251	Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax, 1997, 52, 557-560.	2.7	122
252	Childhood bacterial meningitis: Impact of age at illness and acute medical complications on long term outcome Journal of the International Neuropsychological Society, 1997, 3, 147-158.	1,2	56

#	Article	IF	Citations
253	Fatal granulomatous amoebic encephalitis caused by <i>Balamuthia mandrillaris</i> . Medical Journal of Australia, 1997, 167, 82-84.	0.8	54
254	Antibiotic management of pneumococcal infections in an era of increased resistance. Journal of Paediatrics and Child Health, 1997, 33, 287-295.	0.4	16
255	Childhood bacterial meningitis: impact of age at illness and acute medical complications on long term outcome. Journal of the International Neuropsychological Society, 1997, 3, 147-58.	1.2	17
256	Streptococcal pharyngitis in a paediatric emergency department. Medical Journal of Australia, 1996, 165, 420-423.	0.8	29
257	An infant with fever and convulsions. European Journal of Pediatrics, 1996, 155, 517-518.	1.3	4
258	Late-onset infections of infants in neonatal units. Journal of Paediatrics and Child Health, 1996, 32, 158-161.	0.4	72
259	Risk factors for adverse outcomes of bacterial meningitis. Journal of Paediatrics and Child Health, 1996, 32, 457-462.	0.4	62
260	Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. Journal of Paediatrics and Child Health, 1996, 32, 211-217.	0.4	23
261	Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis., 1996, 21, 267-275.		261
262	Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy, 1996, 37, 1155-1164.	1.3	83
263	Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis., 1996, 21, 267.		6
264	Helicobacter pylori and Recurrent Abdominal Pain in Children. Journal of Pediatric Gastroenterology and Nutrition, 1996, 22, 148-152.	0.9	42
265	Systemic bacterial and fungal infections in infants in Australian neonatal units. Medical Journal of Australia, 1995, 162, 198-201.	0.8	100
266	Sonographic measurement of renal enlargement in children with acute pyelonephritis and time needed for resolution: implications for renal growth assessment American Journal of Roentgenology, 1995, 165, 405-408.	1.0	19
267	Prevention of Neonatal Group B Streptococcal Sepsis: Is Routine Antenatal Screening Appropriate. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1995, 35, 120-126.	0.4	30
268	Prevalence of Helicobacter pylori infection in asymptomatic children. Journal of Paediatrics and Child Health, 1995, 31, 537-541.	0.4	15
269	Patients with enteric adenovirus gastroenteritis admitted to an Australian pediatric teaching hospital from 1981 to 1992. Journal of Clinical Microbiology, 1995, 33, 131-136.	1.8	77
270	Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ: British Medical Journal, 1995, 310, 1571-1572.	2.4	327

#	Article	IF	Citations
271	Adverse outcomes of bacterial meningitis in school-age survivors. Pediatrics, 1995, 95, 646-56.	1.0	118
272	Vesicoureteral reflux: an accurate predictor of acute pyelonephritis in childhood urinary tract infection?. Radiology, 1994, 190, 413-415.	3.6	66
273	Risk factors in the development of early renal cortical defects in children with urinary tract infection American Journal of Roentgenology, 1994, 162, 1393-1397.	1.0	76
274	Position Paper: Chemoprophylaxis for Haemophilus and meningococcal infections. Journal of Paediatrics and Child Health, 1994, 30, 9-11.	0.4	5
275	Elevated exoenzyme expression byPseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis Pediatric Pulmonology, 1993, 15, 135-139.	1.0	39
276	Aminotransferase activity in celiac disease. Journal of Pediatrics, 1993, 123, 1017-1018.	0.9	2
277	Analysis of homotypic and heterotypic serum immune responses to rotavirus proteins following primary rotavirus infection by using the radioimmunoprecipitation technique. Journal of Clinical Microbiology, 1993, 31, 377-385.	1.8	37
278	The pathogenesis of <i>Pseudomonas aeruginosa</i> lung infections in cystic fibrosis. Journal of Paediatrics and Child Health, 1992, 28, 4-11.	0.4	7
279	Role of coproantibody in clinical protection of children during reinfection with rotavirus. Journal of Clinical Microbiology, 1992, 30, 1678-1684.	1.8	171
280	Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis. Medical Journal of Australia, 1992, 156, 662-663.	0.8	7
281	Clostridium sordellii infection and toxin neutralization. Pediatric Infectious Disease Journal, 1990, 9, 582-585.	1.1	7
282	Dexamethasone treatment for bacterial meningitis. Journal of Paediatrics and Child Health, 1990, 26, 311-313.	0.4	3
283	Comparison of rotavirus immunoglobulin A coproconversion with other indices of rotavirus infection in a longitudinal study in childhood. Journal of Clinical Microbiology, 1990, 28, 1367-1374.	1.8	72
284	Subinhibitory antibiotics reduce Pseudomonas aeruginosa tissue injury in the rat lung model. Journal of Antimicrobial Chemotherapy, 1989, 24, 937-945.	1.3	37
285	Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations. Antimicrobial Agents and Chemotherapy, 1989, 33, 41-47.	1.4	112
286	Evaluation of end-point titration, single dilution and capture enzyme immunoassays for measurement of antirotaviral IgA and IgM in infantile secretions and serum. Journal of Virological Methods, 1989, 26, 53-65.	1.0	28
287	Serum aspartate aminotransferase levels after rotavirus gastroenteritis. Journal of Pediatrics, 1988, 112, 597-600.	0.9	34
288	Comparison of serum and mucosal antibody responses following severe acute rotavirus gastroenteritis in young children. Journal of Clinical Microbiology, 1988, 26, 732-738.	1.8	116

#	Article	IF	CITATIONS
289	Comparison between children treated at home and those requiring hospital admission for rotavirus and other enteric pathogens associated with acute diarrhea in Melbourne, Australia. Journal of Clinical Microbiology, 1986, 24, 395-399.	1.8	23
290	Combination of salbutamol inhalational powder and tablets in asthma Archives of Disease in Childhood, 1983, 58, 283-285.	1.0	9
291	Spread of rotavirus within families: a community based study BMJ: British Medical Journal, 1983, 287, 575-577.	2.4	60
292	Salbutamol: tablets, inhalational powder, or nebuliser?. BMJ: British Medical Journal, 1981, 282, 105-106.	2.4	25
293	Probiotics for preventing acute otitis media in children. The Cochrane Library, 0, , .	1.5	6